



14 February 2022

ASX Announcement

### **Release of shares from escrow**

BCAL Diagnostics Limited (ASX: BDX) (BCAL or Company) advise in accordance with Listing Rule 3.10A that 20,596,692 ordinary shares in the Company will be released from escrow on 20 February 2022.

This announcement authorised by Guy Robertson, Company Secretary.

### **Investor & Media Enquiries**

Matthew Wright  
NWR Communications  
[matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)  
+61 451 896 420

### **About BCAL Diagnostics**

BCAL Diagnostics Limited is an Australian screening and diagnostic company committed to the early, accurate diagnosis of breast cancer, and therefore early intervention and improved outcomes for women. Over the past decade BCAL has developed a non-invasive blood test for the detection of breast cancer, with results to date demonstrating 91% specificity and 87% accuracy. The test is initially designed to complement current imaging technologies, such as the mammogram, with the aim of becoming a monitoring and screening tool suitable for women of all ages and backgrounds in any location. With more than two million new cases of breast cancer diagnosed globally each year, a substantial opportunity exists for BCAL to improve patient outcomes. BCAL has partnered with global integrated cancer care and cardiac provider GenesisCare to conduct clinical research required for regulatory approvals across several jurisdictions, commercialisation and market entry points.

Founded in 2010, BCAL is headquartered in Sydney and listed on the Australian Securities Exchange (ASX:BDX). For more information: <https://www.bcaldiagnostics.com/>